Zevra Therapeutics, Inc. (ZVRA)
11.56
-0.29
(-2.45%)
USD |
NASDAQ |
Aug 28, 16:00
11.56
0.00 (0.00%)
After-Hours: 16:56
Zevra Therapeutics Cash from Operations (Quarterly) : 17.03M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.03M |
| March 31, 2026 | 6.142M |
| December 31, 2025 | 5.516M |
| September 30, 2025 | 4.709M |
| June 30, 2025 | -3.601M |
| March 31, 2025 | -8.222M |
| December 31, 2024 | -16.25M |
| September 30, 2024 | -18.14M |
| June 30, 2024 | -19.11M |
| March 31, 2024 | -16.16M |
| December 31, 2023 | -16.16M |
| September 30, 2023 | -4.628M |
| June 30, 2023 | -8.704M |
| March 31, 2023 | -4.045M |
| December 31, 2022 | -4.462M |
| September 30, 2022 | -6.598M |
| June 30, 2022 | -4.172M |
| March 31, 2022 | -3.485M |
| December 31, 2021 | -0.848M |
| September 30, 2021 | -2.73M |
| June 30, 2021 | 16.60M |
| March 31, 2021 | -5.467M |
| December 31, 2020 | -1.059M |
| Date | Value |
|---|---|
| September 30, 2020 | -1.051M |
| June 30, 2020 | 2.193M |
| March 31, 2020 | -2.022M |
| December 31, 2019 | -3.098M |
| September 30, 2019 | -2.229M |
| June 30, 2019 | -7.344M |
| March 31, 2019 | -11.07M |
| December 31, 2018 | -15.18M |
| September 30, 2018 | -15.95M |
| June 30, 2018 | -9.152M |
| March 31, 2018 | -14.10M |
| December 31, 2017 | -6.936M |
| September 30, 2017 | -10.17M |
| June 30, 2017 | -6.473M |
| March 31, 2017 | -9.521M |
| December 31, 2016 | -9.649M |
| September 30, 2016 | -7.984M |
| June 30, 2016 | -8.274M |
| March 31, 2016 | -3.865M |
| December 31, 2015 | -6.403M |
| September 30, 2015 | -4.611M |
| June 30, 2015 | -5.255M |
| March 31, 2015 | -3.999M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Innoviva, Inc. | 51.97M |
| Collegium Pharmaceutical, Inc. | 71.32M |
| Johnson & Johnson | 8.616B |
| Ligand Pharmaceuticals, Inc. | 24.02M |
| Harrow, Inc. | -9.755M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 31.45M |
| Cash from Financing (Quarterly) | 1.585M |
| Free Cash Flow | 32.62M |
| Free Cash Flow Per Share (Quarterly) | 0.2741 |
| Free Cash Flow to Equity (Quarterly) | 16.47M |
| Free Cash Flow to Firm (Quarterly) | 16.82M |
| Free Cash Flow Yield | 4.75% |